Bristol Myers Squibb to acquire MyoKardia to gain access to mavacamten

Bristol Myers Squibb (BMS) has agreed to acquire California-based clinical-stage biopharma company MyoKardia for $13.1 billion, to gain access to the latter’s cardiovascular drug candidate ... Read More